2008, Manufacturing and Patients - Primary Care Digest

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2008

Manufacturing

Patients

Psilocybin in Serious Illness: James Downar, Ali John Zarrabi and Margaret Ross

GeriPal

MAY 8, 2025

Summary Transcript CME Summary Weve covered psychedelics on the podcast beforefirst in 2019 with Ira Byock, where we explored their potential role in medicine , and then again in 2023 with Stacy Fischer, Brian Anderson, and Theora Cimino, focusing on the reasons to approach psychedelic use in patients with caution. Then fast forward a year.

Illness

Illness IT Patient-Centered Patients

FDA-Approved Labeling: Is Enough Enough?

FDA Law

AUGUST 21, 2023

After all, the labeling is intended to do exactly that: it informs patients and prescribers of the risks to ensure the product is used effectively and in a manner that mitigates risks, according to FDA’s understanding of the relevant science. Just like it was over a decade ago in Pliva v. The same considerations ring true for OTC drugs.

Manufacturing

Manufacturing Consulting Healthcare Professional Vaccination

Psilocybin in Serious Illness: James Downar, Ali John Zarrabi and Margaret Ross

FDA-Approved Labeling: Is Enough Enough?

Stay Connected